Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Gastroenterology
Published in: Indian Journal of Gastroenterology 3/2010

01-05-2010 | Letters

Does plasma resistin level have a role in predicting inflammatory bowel disease activity?

Authors: N. A. Abdel Kader, F. A. Ali El-Din, E. A. A. Khatab, N. E. ELAbd

Published in: Indian Journal of Gastroenterology | Issue 3/2010

Login to get access

Excerpt

Resistin is a secretory adipokine with proinflammatory properties in humans [1]. It has emerged during this decade as a promising inflammatory marker in various diseases [2]. This study aimed to investigate the role of serum resistin as a marker of disease activity in inflammatory bowel disease (IBD) and its correlation with clinical, endoscopic, histological and inflammatory parameters of IBD. …
Literature
1.
Almehed K, d’Elia HF, Bokarewa M, Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther. 2008;24:R15.
2.
Karmiris K, Koutroubakis IE. Resistin: another rising biomarker in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2007;19:1035–7.CrossRefPubMed
3.
Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.CrossRefPubMed
4.
Best WR, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.PubMed
5.
Walmsey RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.CrossRef
6.
Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982;12:351–9.
7.
López Morante AJ, Sáez-Royuela F, Yuguero del Moral L, Martín Lorente JL, Ojeda Giménez C. The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease. Rev Esp Enferm Dig. 1993;83:5–9.PubMed
8.
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100–5.CrossRefPubMed
9.
Konrad A, Lehrke M, Schachinger V. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–4.CrossRefPubMed
Metadata
Title
Does plasma resistin level have a role in predicting inflammatory bowel disease activity?
Authors
N. A. Abdel Kader
F. A. Ali El-Din
E. A. A. Khatab
N. E. ELAbd
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Indian Journal of Gastroenterology / Issue 3/2010
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-010-0008-1

Other articles of this Issue 3/2010

Indian Journal of Gastroenterology 3/2010 Go to the issue

Original Article

How sustained is sustained viral response in patients with hepatitis C virus infection?

Original Article

Complete genome sequences of hepatitis C virus subtype 3i and 3a subtype isolates from India

Gastroenterology research

Gastroenterology elsewhere

Image

Development of multiple peribiliary cysts following acute alcoholic hepatitis

Image

Endoscopic ultrasound in biliary fasciolosis

Original Article

Statin use does not prevent recurrent adenomatous polyp formation in a VA population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits